



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/297,486	06/14/1999	JOHN FRANCIS MARTIN	GJE-30	9834
23557	7590	05/04/2005	EXAMINER	
SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION PO BOX 142950 GAINESVILLE, FL 32614-2950			SCHNIZER, RICHARD A	
			ART UNIT	PAPER NUMBER
			1635	
DATE MAILED: 05/04/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/297,486	MARTIN ET AL.	
	Examiner	Art Unit	
	Richard Schnizer, Ph. D	1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 29 July 2004.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-6,8,9 and 39-42 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-6,8,9 and 39-42 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 04 April 2002 is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____



DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/29/04 has been entered.

Applicant requested a 3 month suspension with the filing of an RCE. This period has expired and prosecution is resumed.

An amendment was received and entered on 7/29/04. Claim 7 was canceled and claims 39-42 were added as requested.

Claims 1-6, 8, 9 and 39-42 are pending and under consideration in this Office Action.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-6, 8, 9 and 39-42 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for methods of inhibiting intimal hyperplasia at a site in a blood vessel in a rabbit, by periadventitial administration at the site of a DNA expression vector encoding vascular endothelial growth factor (VEGF),

does not reasonably provide enablement for treatment of any vascular disorder in any species other than a rabbit. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims, for the reasons of record in Paper Nos. 15 and 18.

Claims 1-6, 8, 9, and 39-42 are drawn to methods of inhibiting or reducing intimal hyperplasia. The recited method steps require administration of a nucleic acid encoding human VEGF. The nucleic acid must be delivered periadventitially to a site where intimal hyperplasia is present or may occur. The claims require inhibition or reduction of hyperplasia. In the previous Action, the phrase "whereby intimal hyperplasia of the blood vessel is ... reduced" was interpreted as embracing reversal of existing hyperplasia. However, the specification was carefully reconsidered, and there was no evidence that Applicant wished to embrace reversal of existing hyperplasia by this phrase, but instead focused on inhibiting hyperplasia, i.e. reducing or limiting the extent limiting the extent of hyperplasia. Claims 39-42 are drawn to methods of delivery of a human VEGF protein to a cell of a blood vessel whose endothelium is intact by periadventitial administration of a nucleic acid encoding the human VEGF. The specification discloses no other purpose for performing this method than for inhibiting intimal hyperplasia for the purpose of treating or prevention of stenosis or restenosis. As a result, claims 39-42 face the same enablement issues as claims 1-6, 8, and 9.

The specification teaches a working example in which plasmid expression vectors encoding VEGF were complexed with liposomes and delivered to the adventitial

Art Unit: 1635

surface of a rabbit carotid artery underneath a silicone collar. It was previously shown that placement of a silicone collar on a rabbit carotid artery causes intimal hyperplasia. Injection of VEGF plasmid/liposome complexes inhibited intimal hyperplasia, but this inhibition decreased after two weeks, probably due to a loss of transient gene expression. See the specification at page 33, lines 11-22, and page 36, lines 20-26.

Nucleic acid-mediated therapy

At the time the invention was made, successful implementation of gene therapy protocols was not routinely obtainable by those skilled in the art. This is reflected by three recently published reviews. Orkin (Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995) teaches that “[s]ignificant problems remain in all basic aspects of gene therapy. Major difficulties at the basic level include shortcomings in all current transfer vectors and an inadequate understanding of the biological interaction of these vectors with the host”, (page 1, item 3). Orkin teaches that problems exist in delivering nucleic acid sequences to the appropriate target cell or tissue and achieving the appropriate level of expression within that cell or tissue (page 9). Verma et al (Nature 389: 239-242, 1997) teach that “[t]here is still no single outcome that we can point to as a success story (p. 239, col 1). The authors state further, “[t]hus far, the problem has been the inability to deliver genes efficiently and to obtain sustained expression” (p.239, col. 3). Anderson (Nature 392:25-30, 1998) confirms the unpredictable state of the art, stating that “[t]here is still no conclusive evidence that a gene-therapy protocol has been successful in the treatment of human disease” (p. 25, col. 1) and concluding, “[s]everal major deficiencies

still exist including poor delivery systems, both viral and non-viral, and poor gene expression after genes are delivered" (p.30).

With specific respect to therapies based on the transfer of VEGF to the arterial wall, Laitinen (Pharm. Res. 4744): 251-254, 4/1998) teaches that although promising effects on cardiovascular diseases have been noted by adventitial delivery of genes in animal models using the collar device disclosed at page 16, lines 21-23 of the specification, "further studies regarding gene transfer techniques, vectors, and safety of procedures are needed before a full therapeutic potential of gene therapy in vascular diseases can be evaluated." See abstract. See also sentence bridging pages 252 and 253, and last sentence of CONCLUSIONS on page 253. Thus the treatment of vascular diseases in general by delivery of VEGF nucleic acids was unpredictable at the time the invention was filed.

Relevance of animal models of intimal hyperplasia to human disease and treatment

The prior art teaches that successful treatment of intimal hyperplasia in small animal models is not predictive of success in other animals, particularly in humans. Muller et al (J. Amer. Coll. Cardiol. 19(2):418-432, 1992) teach that, as of 1992, greater than 50 studies had shown that at least 9 different classes of pharmacological agents inhibit intimal proliferation in response to arterial injury in animal models. However, none of these agents reproducibly reduced the incidence of restenosis after coronary balloon angioplasty in humans. To explain these results, Muller considered the differences between the various systems. Significant interspecies and intraspecies

differences were found to exist among the various animal models, particularly with respect to the extent and composition of neointimal thickening, drug and lipid metabolism, and the activity of coagulation and fibrinolytic systems. The instant specification teaches a single example of inhibition of intimal thickening at the precise site of VEGF expression vector administration in a rabbit model of intimal hyperplasia. See Example 1, pages 33-38. The specification teaches no example of reversal of intimal hyperplasia in any model. With respect to rabbit models, Muller notes that rabbit arteries are not necessarily structurally equivalent to human arteries. For example, the amount of elastin in the media of coronary arteries is less than that in larger mammals, the intima is thinner, and the subendothelial space between the endothelium and the internal elastic lamina is very narrow and virtually acellular. A similar intimal structure is found in the arteries of humans only during fetal and early neonatal life. See paragraph bridging columns 1 and 2 on page 420. Muller teaches that these differences may account for the variability in sensitivity of various animal models to treatments, and should be considered carefully in the interpretation of experimental studies. See abstract. Also, after reviewing rat, rabbit, dog, non-human primate, and pig models Muller found that it was "clear that there are major differences among the animal models, particularly in terms of the nature of arterial injury and the composition of the neointima. It could be expected, therefore, that a pharmacological therapy that is effective in one animal model may be ineffective in another species or in humans." See page 426, column 2, first full paragraph. Thus Muller clearly indicates that results in one

animal model are not necessarily predictive of results in another animal model due to physiological differences between the models.

Lafont et al (Ann. Card. Ang. 44(7): 349-353, 9/1995), reviewed the results of fifteen years of research prior to 1995, and conclude that “[a]ll the restenosis strategies based on inhibition of smooth muscle cell proliferation, which successfully limited restenosis in animal models have failed in man, due to hazardous extrapolations from experimental models which are very different from the atheromatous lesions observed in man”. See abstract. Lafont et al (Card. Res. 39(1): 50-59, 7/1998) further indicates that while animal models may be useful for determining the mechanism of a drug on smooth muscle cell proliferation, positive results should not be interpreted to mean that a given treatment will function in humans. “The extrapolation of animal studies directly to man is unreasonable given the vast differences between animal models and man, and the complexity of the restenotic process.” See page 54, column 2, lines 3-12. In fact, the unpredictability in extrapolating results of such studies to humans was still noted in 1999 after the priority date of the instant application, when Johnson et al taught that small animal models “lacked efficacy in predicting the success of interventions to inhibit restenosis in humans”, and found that small animal models fail to closely simulate human atherosclerosis and stenotic lesions. See abstract. Finally, Appleby and Kingston (Current Gene Therapy 4:153-182, 2004) reviewed the state of the art of restenosis gene therapy after the time of the invention. These authors relate that despite promising results from numerous animal studies, there has been a general failure to obtain similar results in humans. This is primarily due to an incomplete

understanding of the vascular biology of restenosis which makes it difficult to select therapeutic genes, dissimilarity between humans and the animal models under study, and difficulty in obtaining localized gene transfer into coronary arteries *in vivo*. The authors conclude that progress in each area will be required before gene therapy in the vasculature becomes a clinical reality. See abstract and last two paragraphs on page 176. For these reasons, the enabled use of the claimed invention is limited to the treatment of rabbits.

In summary, at the time of the invention, those of skill in the art recognized that one could not accurately extrapolate positive results from small animal models of smooth muscle cell proliferation to other animals, particularly humans; the specification fails to provide guidance that would allow such extrapolation; the specification exemplifies only inhibition of hyperplasia in a rabbit model, and not reversal of hyperplasia; and the specification fails to provide any working example of treatment in any organism other than a rabbit. For these reasons, one of skill in the art could not practice the claimed methods commensurate in scope with the claims without undue experimentation.

Applicant's response filed 7/29/04 contained a request for 3 month suspension of prosecution, and no arguments directed at the enablement rejection. No response has been received in the interim.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the

Art Unit: 1635

unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-6, 8, 9, and 39-42 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 16, 18, 20-25, 27, 33, and 34 of copending Application No. 10/196,345. Although the conflicting claims are not identical, they are not patentably distinct from each other for the following reasons.

Claims 16, 18, 20-25, 27, 33, and 34 of '345 are drawn to methods of treating or inhibiting at least one of stenosis, restenosis, and intimal hyperplasia by applying to the outer layer of a blood vessel a cell-free nucleic acid encoding a VEGF protein. The specification of '345 indicates that the VEGF may be human VEGF165. See paragraph 46. The instant specification indicates that human VEGF165 is instant SEQ ID NO:4. See page 7, lines 26-29. Because '345 teaches the delivery of nucleic acids encoding human VEGF165 (instant SEQ ID NO:4) to the outer surface (adventitia) of a blood vessel, the resulting VEGF expression and inhibition of stenosis, restenosis, and/or intimal hyperplasia is considered to be inherent, and the instant claims are considered obvious variants of claims 16, 18, 20-25, 27, 33, and 34 of '345.

Art Unit: 1635

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Richard Schnizer, whose telephone number is 571-272-0762. The examiner can normally be reached Monday through Friday between the hours of 6:00 AM and 3:30. The examiner is off on alternate Fridays, but is sometimes in the office anyway.

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Andrew Wang, can be reached at (571) 272-0811. The official central fax number is 703-872-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.



Richard Schnizer, Ph.D.